Patents by Inventor GlaxoSmithKline
GlaxoSmithKline has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180221466Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.Type: ApplicationFiled: October 1, 2012Publication date: August 9, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventor: GlaxoSmithKline Biologicals S.A.
-
Publication number: 20150165015Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.Type: ApplicationFiled: October 1, 2012Publication date: June 18, 2015Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventor: GlaxoSmithKline Biologicals S.A.
-
Publication number: 20130280280Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: March 12, 2013Publication date: October 24, 2013Applicant: GLAXOSMITHKLINEInventor: GLAXOSMITHKLINE
-
Publication number: 20130197221Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: GlaxoSmithKline LLCInventor: GlaxoSmithKline LLC
-
Publication number: 20130184263Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.Type: ApplicationFiled: December 14, 2012Publication date: July 18, 2013Applicant: GlaxoSmithKline LLCInventor: GlaxoSmithKline LLC
-
Publication number: 20130167378Abstract: A method of producing a metering valve for use with a pressurised dispensing container for dispensing medicament from said container, the metering valve having a valve stem, a valve member, and outer and inner annular seals, the method comprising assembling the metering valve so that the valve stem is co-axially slidable within the valve member, the valve member and the valve stem define an annular metering chamber with a surface of the valve member forming an internal surface of the metering chamber which, in use, comes into contact with medicament, and the outer and inner annular seals are operative between respective outer and inner ends of the valve member and the valve stem to seal the annular metering chamber therebetween; and wherein the method further comprises the step of subjecting said surface of the valve member to a cold plasma polymerisation treatment of one or more monomers to bond to the surface a layer of a cold plasma polymerised fluorinated hydrocarbon.Type: ApplicationFiled: February 27, 2013Publication date: July 4, 2013Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventor: GlaxoSmithKline Intellectual Property Development Limited
-
Publication number: 20130165415Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.Type: ApplicationFiled: February 19, 2013Publication date: June 27, 2013Applicants: GLAXOSMITHKLINE LLC, SHIONOGI & CO., LTD.Inventors: SHIONOGI & CO., LTD., GLAXOSMITHKLINE LLC
-
Publication number: 20130157977Abstract: This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazole boronic acid compounds for treating cancer.Type: ApplicationFiled: November 12, 2012Publication date: June 20, 2013Applicant: GlaxoSmithKline LLCInventor: GlaxoSmithKline LLC
-
Publication number: 20130158114Abstract: Novel calcilytic compounds and methods of using them are provided.Type: ApplicationFiled: February 11, 2013Publication date: June 20, 2013Applicant: GlaxoSmithKline, LLCInventor: GlaxoSmithKline, LLC
-
Publication number: 20130150363Abstract: The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of: a) a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein R1-R4, p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof. The method of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.Type: ApplicationFiled: January 29, 2013Publication date: June 13, 2013Applicant: GlaxoSmithKlineInventor: GlaxoSmithKline
-
Publication number: 20130142790Abstract: The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of: a) a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein R1—R4, p, and q are as defined; and (b) an erbB inhibitor that inhibits erbB-1 or erbB-2 or erbB-3 receptor or a combination thereof. The method of the present invention addresses a need in the art with the discovery of a combination therapy that shows evidence of being a more effective therapy than previously disclosed therapies.Type: ApplicationFiled: January 29, 2013Publication date: June 6, 2013Applicant: GlaxoSmithKlineInventor: GlaxoSmithKline
-
Publication number: 20130137736Abstract: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.Type: ApplicationFiled: January 24, 2013Publication date: May 30, 2013Applicant: GlaxoSmithKline LLCInventor: GlaxoSmithKline LLC
-
Publication number: 20130072690Abstract: Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.Type: ApplicationFiled: November 15, 2012Publication date: March 21, 2013Applicant: GLAXOSMITHKLINE LLCInventor: GLAXOSMITHKLINE LLC
-
Publication number: 20130072487Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.Type: ApplicationFiled: November 2, 2012Publication date: March 21, 2013Applicant: GLAXOSMITHKLINE LLCInventor: GLAXOSMITHKLINE LLC